Mixtard 30 (Insulin Human)

Insulin human, the active ingredient in Mixtard 30, is a short‑acting insulin presented as an injectable solution for subcutaneous administration. It is used to lower elevated blood glucose levels in patients with diabetes mellitus, including both type 1 and type 2, and is marketed in the European Union.

GNH USA supplies Mixtard 30 as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing regulatory‑approved batches that meet EU quality standards and supporting global procurement for diabetes care programs.

Mixtard 30 is a human insulin formulation indicated for the management of hyperglycaemia in diabetes mellitus, providing both basal and rapid‑acting coverage.

- Type 1 diabetes mellitus: supplies both basal and mealtime insulin to achieve target glycaemic levels and reduce risk of ketoacidosis. - Type 2 diabetes mellitus: adds exogenous insulin to improve glucose control when diet, exercise, and oral agents are inadequate. - Hyperglycaemic crisis (e.g., diabetic ketoacidosis): can be used under medical supervision to rapidly lower plasma glucose while other therapies are initiated.

Common Side Effects: - Hypoglycaemia: low blood sugar episodes, especially if meals are missed or dose is excessive. - Injection site reactions: redness, swelling, or itching at the injection site. - Weight gain: increased adipose tissue due to improved glucose utilization. - Lipodystrophy: localized fat accumulation or loss with repeated injections. - Edema: mild fluid retention, particularly in the lower extremities. - Headache: transient mild headache after injection.

Serious or Rare Side Effects: - Severe hypoglycaemia leading to seizures or loss of consciousness. - Anaphylactic reaction: hives, difficulty breathing, or swelling of the face. - Insulin allergy: systemic rash or urticaria. - Hypokalemia: low potassium levels, potentially causing cardiac arrhythmia. - Insulin antibodies: may alter insulin action or cause immune complex reactions.

Before using Mixtard 30, patients should be aware of the following precautions: - Blood glucose monitoring: check levels regularly to adjust dose appropriately. - Dose adjustments: modify insulin dose when initiating, changing diet, or during illness. - Renal impairment: use caution as reduced clearance may increase hypoglycaemia risk. - Known hypersensitivity: avoid if allergic reactions to human insulin have occurred. - Pregnancy category B: use only if the potential benefit justifies the potential risk to the fetus. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Mixtard 30 may interact with other medicines as follows:

Major Interactions (Avoid): - Sulfonylureas: combined effect can cause severe hypoglycaemia. - Beta‑blockers: may mask typical hypoglycaemia symptoms such as tachycardia. - Glucocorticoids: can reduce insulin effectiveness, requiring dose increase.

Moderate Interactions (Monitor Closely):\n- ACE inhibitors: may enhance insulin sensitivity, increasing hypoglycaemia risk. - Thiazide diuretics: can raise blood glucose, potentially necessitating higher insulin doses. - Alcohol: may potentiate hypoglycaemia, especially with missed meals.